Overview

RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction.

Eligibility

Inclusion Criteria:

• Females ≥ 18 years up to 85 years old
• Individuals referred to hospitals for diagnosis of breast cancer
• Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance
• Availability of pathological report (surgical specimen)
• Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit)
• Availability of treatment response

Exclusion Criteria:

• Patient with incomplete or low-quality data (radiological, pathological or clinical)